Skip to Main content Skip to Navigation
Journal articles

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR -Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments

Marc Denis 1 Jaafar Bennouna 2
1 CRCINA-ÉQUIPE 2 - Clinical and Translational Research in Skin Cancer
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
2 CRCINA-ÉQUIPE 4 - Immunogenic Cell Death and Mesothelioma Therapy
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
Abstract : Non-small cell lung cancer (NSCLC) is one of the most efficient models for precision medicine in oncology. The most appropriate therapeutic for the patient is chosen according to the molecular characteristics of the tumor, schematically distributed between immunogenicity and oncogenic addiction. For this last concept, advanced NSCLC with epidermal growth factor receptor (EGFR) mutation is one of the most illustrative models. EGFR-tyrosine kinase inhibitors (TKIs) are the therapeutic backbone for this type of tumor. The recent development of a third-generation TKI, osimertinib, has been a new step forward in the treatment of NSCLC patients. In this article, we first review the clinical development of osimertinib and highlight its efficacy results. We then present the most frequent tumor escape mechanisms when osimertinib is prescribed in first line: off-target (MET amplification, HER2 amplification, BRAF mutation, gene fusions, histologic transformation) and on-target mechanisms (EGFR mutation). Finally, we discuss subsequent biomarker-driven treatment strategies.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03498514
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Tuesday, December 21, 2021 - 9:33:50 AM
Last modification on : Wednesday, January 19, 2022 - 3:44:03 PM

Links full text

Identifiers

Collections

Citation

Marc Denis, Jaafar Bennouna. Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR -Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments. Cancer Management and Research, Dove Medical Press, 2020, Volume 12, pp.12593-12602. ⟨10.2147/CMAR.S218751⟩. ⟨inserm-03498514⟩

Share

Metrics

Les métriques sont temporairement indisponibles